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ABSTRACT
Objective: There are several methodological and practical issues surround-
ing the transferability of economic data that are important to address. A
review of what national guidelines for economic evaluations say about
transferability is important to understand the context in which transferabil-
ity is currently practiced and discussed. Aim of this editorial is to discuss the
results of a study reviewing the positions of various national guidelines in
relation to the transferability and generalizability of data and the methods
suggested for addressing issues of transferability presented in this issue.
Conclusion: The recommendations on good research practices for dealing
with aspects of transferability are ﬁlling an important gap. However, in
order for the applied science of Pharmacoeconomics and Outcomes
Research to make up for its epistemological aim and the aim of providing
normative judgments, the methodological foundation of normative judg-
ments has to be given the same importance as the methodological foun-
dation the scientiﬁc community is seeking to establish as good research
practices.
Keywords: health-care costs, health-care utilization, health economics
methods, health economics, health-state utility.
The question of data generalizabilty and transferability of eco-
nomic and clinical data for economic evaluation is inherent to
every health economic decision problem—at national, regional,
or institutional level—where either data are external to the deci-
sion problem or the relevant subset of data is not providing a
sample size to inform the decision with sufﬁcient certainty. This
affects data transferability between jurisdictions, regions, popu-
lations, and institutions like hospitals and is a result of many
reasons like differences in treatment patterns, severity of disease,
and population characteristics.
With a growing number of jurisdictions requesting economic
data in support of their health technologies allocation decision-
making procedures and with the requests for data being sup-
ported by national guidelines on the conduct of economic
evaluation, it could be seen highly relevant to study current
guidance on the transferability of economic and clinical data for
economic evaluations and its variations. The article “What Do
International Pharmacoeconomic Guidelines Say about Eco-
nomic Data Transferability” in this issue presents the results of a
study reviewing the positions of various national guidelines in
relation to the transferability and generalizability of data and
reviews the methods suggested for addressing issues of transfer-
ability [1].
In the absence of a hypothesis and derived critical implica-
tions no gain in knowledge can be generated from the descriptive
assessment of the guidance on data transferability—in an episte-
mological sense. However, a descriptive approach might be
deemed relevant as baseline to recommend good research prac-
tices in dealing with aspects of transferability including analytic
strategies and guidance for considering the appropriateness of
evidence from other countries [2].
The more population or jurisdiction speciﬁc the data, the less
generalizable/transferable are the data for other populations or
jurisdictions. Not unexpectedly, the review of pharmacoeoco-
nomic guidelines ﬁnds the generalizabilizy/transferability of eco-
nomic data to be limited. Consequently to the nature of the data,
baseline risk has a low transferability, clinical data respective
data on relative risk has high transferability, and resource use and
costs data have low transferability. Only little guidance has been
found on analytical strategies and the transferability of health-
state valuations or utility estimates. This might deﬁne an area
where additional (methodological) guidance will add value for
both the generation and critical review of data in health resources
allocation decisions.
With the inclusion/exclusion criteria for national pharmaco-
economic guidelines being driven by easiness of data accessibility
(obtainable from the ISPOR Web site and language versions
available) the ﬁndings do not only lack generalizability; with the
exclusion of Asian countries the national guidelines of countries
have not been studied where data generalizability/transferability
is of particular relevance.
If the aspiration is to explain differences in national guidelines
and to deduct normative recommendations, we are under differ-
ent methodological constraints. There are two main aspects that
might be worthwhile to critically reﬂect on and that this editorial
would like to propose to the discussion:
1. Optimal level of data generalizability/transferability. The
consideration of generalized/transferred data is a process of
diligent and careful balancing in the context of the decision
problem: the incremental costs of accepting uncertainty
in the estimates versus the incremental beneﬁt of (earlier)
reallocation of health-care resources, the incremental infor-
mational value of additional evidence respective the incre-
mental gain in the accuracy of the estimates, and thus the
decision quality versus the incremental costs to generate and
assess additional data. Any normative recommendation will
have to imply superiority with respect to cost of the
decision-making process and costs and beneﬁts of the impli-
cations of the decision ensuring the incremental beneﬁts
match the incremental cost of additional jurisdiction-
speciﬁc data provided.
2. Optimal regulation of data generalizability/transferability.
Further on, there is the question of effective and efﬁcient
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regulation if a decision has been made about the above.
What should be regulated in “coded” guidance (e.g., in
national pharmacoeconomic guidelines) and at which level
of detail? To what extent is the “case law” of reviewers’
practice a more effective and/or efﬁcient instrument? What
are the costs and beneﬁts of harmonization of requirements
respective regulations versus the beneﬁts of diversity across
decision bodies? What provides static, what provides
dynamic regulative effectiveness and efﬁciency? Dynamic
efﬁciency is an alternative paradigm to neoclassical efﬁ-
ciency. In fact there is likely for various reasons to be
trade-offs between static and dynamic efﬁciency. When we
are considering dynamic efﬁciency good policy cannot be
mechanically judged in terms of whether it achieves the
optimal level of data transferability at the moment. Policy is
a far more nuanced process that has to be carefully evalu-
ated in terms of its effect on the retroactive effects and
adaptive ﬂexibility. Which type of regulation is superior:
guidance on the methods to handle data, the way data
should be reviewed, or the type of data to be generated?
And maybe even more important: What have been the
regulative aims of the respective national pharmacoeco-
nomic guidelines reviewed? The optimal way of regulating
data transferability and generalizability depends on mul-
tiple factors and will likely vary between jurisdictions.
In the absence of a theoretical foundation given by the
authors and in light of the considerations above the author’s
hypothesis that the guidance on transferability is dependent on
the issue date of the guidelines as well as on the “degree of
development of health economic methods” is not comprehen-
sible, the lack of critical implications is absconding the hypoth-
eses from falsiﬁability. Further on the operationalization (e.g.,
iHea members per inhabitant) could be deemed insufﬁcient even
for the hypothesized causality. Difference in the aim of the guide-
lines, size of country, health-care funding, and decision makers
are only listing a few other variables important to consider.
Finally and in conclusion to the train of thoughts above,
national guidance has to be seen in its entity as a mix of coded
and uncoded recommendations and expectations. The actual
implementation and interpretation of the national guidelines in
real-life practice and the level of economic data generalizability/
transferability accepted by assessors is a better proxy of data
generalizability/transferability. With the example of the decision
practice of the National Institute of Clinical Excellence in the UK
the authors provide additional information for one of the
national guidelines incorporated in the review. However, the
generalizability of the observed application in one jurisdiction to
control for the actual implementation is limited.
The authors conclude that the review suggests increasing the
level of standardization, the frequency of national guideline
updates, and the level of detail to be incorporated. Solely based
on the expected burden or costs associated with increasing
data requirements the normative recommendations appear
unbalanced and are not supported by the design of the study
conducted.
In summary, there are several methodological and practical
issues surrounding the transferability of economic data that
are important to address. A review of what national guidelines
for economic evaluations say about transferability is important
in understanding the context in which transferability is currently
practiced and discussed. Recommendations on good research
practices for dealing with aspects of generalizability/
transferability are ﬁlling an important gap. However, in order for
the applied science of Pharmacoeconomics and Outcomes
Research to make up for its epistemological aim and the aim of
providing normative judgments, the methodological foundation
of normative judgments has to be given the same importance as
the methodological foundation the scientiﬁc community is
seeking to establish as good research practices.
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